Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $24,540 | $28,318 | $28,541 | $34,124 | $45,043 |
| Gross Profit | $19,057 | $21,006 | $21,912 | $27,042 | $36,624 |
| Operating Income | N/A | N/A | N/A | N/A | N/A |
| Net Income | $6,194 | $5,582 | $6,245 | $5,240 | $10,590 |
Over the five-year period from 2020 to 2024, Eli Lilly’s revenue has shown an overall upward trajectory, growing from USD 24.5 billion in 2020 to USD 45.0 billion in 2024. Notably, the company experienced modest increases between 2020 and 2022—with revenue rising by about 16% overall—but then saw more significant leaps, including a nearly 19% rise from 2022 to 2023 and an impressive 32% increase from 2023 to 2024. Gross profit follows a similar upward trend, growing from USD 19.1 billion to USD 36.6 billion during the same period, which indicates that the company’s cost efficiencies and/or product mix may be improving in tandem with higher sales volumes. It is important to note that the operating income is consistently reported as zero throughout these years, a point that suggests either a unique reporting approach or aggregated figures where operating income does not distinctly capture the operational profitability. Net income trends, however, exhibit more volatility. After an initial figure of USD 6.2 billion in 2020, net income fell by roughly 10% in 2021 and dipped slightly in 2023 before nearly doubling from USD 5.2 billion in 2023 to USD 10.6 billion in 2024. This significant swing in 2024 aligns with robust revenue growth and could be driven by factors such as improved product mix execution, successful introduction of new therapies, or favorable market conditions in the pharmaceutical industry. Overall, while the revenue and gross profit trajectories underscore strong operational scaling, the net income variability underscores the need for closer scrutiny of non-operating factors and cost management. Based solely on these financial metrics, Eli Lilly appears to be on a sustainable growth path, bolstered by both top-line expansion and improved bottom-line performance in the most recent period.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.